Podcast 36: CDMOs/CMOs Ramp Up Biomanufacturing Capacity

Capital investments are ramping up in biomanufacturing, which continues to be an active area for CDMOs/CMOs in both traditional biologics and new modalities. Which companies are expanding?

Key topics: (see Chapter Markers in drop down menu in audio player above)

  • A roundup of expansion activity (1:12)
  • Fujifilm Diosynth Biotechnologies (1:21)
  • Samsung Biologics (5:02)
  • Lonza (6:44)
  • Boehringer Ingelheim (10:00)
  • Thermo Fisher Scientific (10:37)
  • Catalent (13:59)
  • WuXi Biologics (17:32)



Subscribe to our e-newsletter at www.dcatvci.org

Follow us on Twitter @DCATvci

Support the show